Background and Objectives It is currently difficult to accurately predict who, after the index event of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), will develop relapsing disease (R-MOGAD). Several clinical features have been reported as possibly predictive, but none have been validated in...
Matthew Human, C. Gilmartin, Athanasios Papathanasiou et al.· Neurology(R) neuroimmunology...· 0 citations
In this longitudinal study, mean sGFAP and sNfL levels remained stable over 9 years of sequential measurements during relapse-free periods, supporting the relapse-driven nature of NMOSD pathology.
P. Siriratnam, C. Dunai, Nkongho Egbe Franklyn et al.· Journal of Neurology Neurosu...· 0 citations
Key updates include expansion of dissemination in space to incorporate the optic nerve, integration of relapsing and progressive onset MS within a unified diagnostic framework, provision for diagnosis in selected asymptomatic individuals, dispensing with the requirement for dissemination of time in certain situations a...
P. Siriratnam, Mineesh Datta, Katherine A. Buzzard et al.· Autoimmunity Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
